Akèy › Lukemi lenfositè kwonik › Wisconsin › Milwaukee
Etid klinik pou Lukemi lenfositè kwonik nan Milwaukee, WI
15 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Milwaukee (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
- UW Cancer Center at ProHealth Care, Waukesha · 17 mi lwen
- ProHealth D N Greenwald Center, Mukwonago · 25 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- ak 9 plis
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Ap rekriteFaz 3
- Medical College of Wisconsin, Milwaukee
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Medical College of Wisconsin, Milwaukee
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- The Medical College of Wisconsin, Milwaukee
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- Medical College of Wisconsin, Milwaukee
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Medical College of Wisconsin, Milwaukee
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Ap rekriteFaz 1/2
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- The Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Ap rekriteEtid obsèvasyon
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Ap rekriteEtid obsèvasyon
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Cincinnati, OH14 etid
- Chicago, IL14 etid
- Nashville, TN13 etid
Lòt etid nan Milwaukee
- Kansè nan tete23 etid
- Kansè Poumon ki pa ti selil22 etid
- Kansè (tout kalite)22 etid
- Kansè poumon21 etid
- Myelom Miltip21 etid
- Kansè pwostat20 etid
- Limfòm folikilè19 etid
- Kansè pankreyas18 etid
- Limfòm Non-Hodgkin18 etid
- Kansè ovè17 etid
- Leksemi mieloïd egi17 etid
- Limfòm Burkitt16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.